Biotech Values

[genisi]

Re: GENZ buys rights to Campath for MS from Bayer AG

I wonder if the recent news about a potential treatment for PML had an impact on the purchase decision?

I don't think it's the IPLEX since the main safety issue for Campath, which also caused a clinical hold in 2005 has been ITP not PML. Perhaps the faster than expected completion of enrollment in the first phase III Campath in naive MS patients had something to do with it.